▲ +51.72% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Anavex Life Sciences in the last 3 months. The average price target is $17.60, with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 51.72% upside from the last price of $11.60.
The current consensus among 5 contributing investment analysts is to buy stock in Anavex Life Sciences. This Buy consensus rating has held steady for over two years.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.